Zevra Therapeutics Inc
NASDAQ:ZVRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zevra Therapeutics Inc
Cash from Investing Activities
Zevra Therapeutics Inc
Cash from Investing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Investing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zevra Therapeutics Inc
NASDAQ:ZVRA
|
Cash from Investing Activities
$18.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Investing Activities
-$23.6B
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-12%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Investing Activities
-$4.1B
|
CAGR 3-Years
-57%
|
CAGR 5-Years
18%
|
CAGR 10-Years
-10%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Investing Activities
-$1.4B
|
CAGR 3-Years
56%
|
CAGR 5-Years
21%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Investing Activities
-$13.7B
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Investing Activities
-$11B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-37%
|
CAGR 10-Years
N/A
|
|
Zevra Therapeutics Inc
Glance View
Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 36 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. The company employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older.
See Also
What is Zevra Therapeutics Inc's Cash from Investing Activities?
Cash from Investing Activities
18.1m
USD
Based on the financial report for Dec 31, 2025, Zevra Therapeutics Inc's Cash from Investing Activities amounts to 18.1m USD.
